In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y

Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0016. Online ahead of print.ABSTRACTRay KK, Nicholls SJ, Li N, et al; CLEAR OUTCOMES Committees and Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12:19-28. 38061370.PMID:38560908 | DOI:10.7326/J24-0016
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Source Type: research